Entia Biosciences, Inc. (ERGO)
Entia Biosciences, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Sherwood, OR, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6,732. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -554.7%. Its beta of 3.27 implies it has historically moved more than the broad market.
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
Entia Biosciences, Inc. is most often compared with the following Healthcare names: